Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-infusion colistin for prevention of colistin-induced nephrotoxicity
IRCT20230225057533N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of colistin in Acinetobacter baumannii infection and Multidrug-resistant Klebsiella pneumoniae (MDR-KP) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Drug toxicity. Started Mar 2023; status: completed.
02
Drugs
colistin
03
Conditions
Acinetobacter baumannii infectionMultidrug-resistant Klebsiella pneumoniae (MDR-KP)
Beyond the preview
Go deeper on IRCT20230225057533N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230225057533N1.